

Category :**ICU organization**

A121 - Limitation of life-sustaining treatment in critically ill patients admitted in icu with sars-cov-2 pneumonia.

A Estella¹ ; M Recuerda² ; A Garrino³ ; P Bustelo³ ; C De La Fuente⁴ ; JL García Garmendia⁵ ; J Garnacho- Montero⁶ ; S Group of work Infectious diseases Andalusian Society of Intensive Care SAMIUC⁷
¹Intensive Care Unit University Hospital of Jerez. INiBICA Medicine department Cadiz University, Intensive & Critical Care, Cadiz , Spain, ²University hospital of Puerto Real, Intensive Care Unit University Hospital of Puerto Real , Puerto Real, Spain, ³University Hospital of Jerez, Intensive Care Unit University Hospital of Jerez , Jerez, Spain, ⁴University hospital Reina Sofia of Córdoba, Intensive Care Unit University Hospital Reina Sofia of Córdoba, Córdoba, Spain, ⁵Hospital San Juan de Dios Bormujos, Intensive Care Unit. Hospital San Juan de Dios Bormujos., Bormujos, Sevilla, Spain, ⁶University Hospital Virgen Macarena Sevilla, Intensive Care Unit University Hospital Virgen Macarena Sevilla, Sevilla, Spain, ⁷Intensive Care Unit University Hospital of Jerez. INiBICA Medicine department Cadiz University, SAMIUC, Cadiz , Spain

Introduction:

Limitation of life-sustaining treatment (LLST) is a recommended practice to avoid futility in critically ill patients who do not improve the medical condition despite invasive treatment. In SARS-CoV-2, LLST during ICU admission has been scarcely studied.

Objective

To describe clinical characteristics of critically ill patients with severe SARS-CoV-2 pneumonia with a clinical decision of LLST during ICU admission.

Methods:

Prospective descriptive multicenter cohort study in 26 Intensive care units (ICU) from Andalusian region in Spain. Consecutive critically ill patients with confirmed SARS-CoV-2 infection were included from March 8 to May 30. Variables analyzed were demographic, severity scores, clinical condition and support therapy. Statistical analysis: Data were analyzed by IBM SPSS 24 and quantitative variables were expressed as a mean \pm standard deviation.

Results:

474 consecutive patients were included. Clinical decision of LLST was recorded in 38 patients, 8,01%. Comorbidities were more frequent in the group of LLST, cardiovascular diseases: 50% versus 37,1%; renal disease: 21,1% versus 8,4%; hypertension: 60,5% versus 45,2%; neurological diseases: 21,1% versus 6,3% and cirrhosis disease: 5,3% versus 1,8%. There were not differences in malignancy and chronic respiratory disease between groups. Percentage of tracheostomy (30,5% Non LLST vs 27%) and haemofiltration (10,4% Non LLST vs 10,5%) was similar. Table 1 shows comparison according clinical decision of LLST.

Conclusion:

Age, comorbidities and severity of organ failure at ICU admission were associated with LLST decision during ICU stay.

Table:

SARS COV 2 Pneumonia	Patients without LLST n:436	Patients with LLST n: 38
Age (years)	60,7 \pm 11,9	70,3 \pm 8,86
APACHE II at admission	12,5 \pm 7,3	17,67 \pm 8,1
SOFA at admission	5,47 \pm 3	7,24 \pm 2,74

SOFA 72 Hours	6,23±3	8,41±3,36
PaO2/FiO2 at admission	140,11±78,1	140,92±85,5
ICU lenght of stay (days)	16,02±11,6	10,66±10,5
Gender (male/female)	315/121	29/9

Comparison according clinical decisión of LLST